Literature DB >> 16371046

Hyperhemolysis syndrome in anemia of chronic disease.

Kamran Darabi1, Sunny Dzik.   

Abstract

BACKGROUND: Occasional cases of delayed hemolytic transfusion reaction (DHTR) demonstrate severe and persistent hemolysis and are referred to as hyperhemolysis syndrome. This syndrome usually occurs in patients with sickle cell disease and possibly thalassemia who receive multiple transfusions. There are few such clinical reports in patients without hemoglobinopathies. CASE REPORT: A 67-year-old woman with anemia and a history of four previous transfusions was admitted with shortness of breath and a hematocrit (Hct) level of 27 percent. The patient was group O with a negative antibody screen. She received 1 unit of electronically cross-matched red blood cells (RBCs) and was discharged. Thirteen days later she returned to hospital with weakness and a Hct level of 23 percent. The antibody screen now demonstrated anti-K alloantibody. The direct antigloblulin test (DAT) was positive with both anti-immunoglobulin G and anti-complement (C3). Anti-K was recovered in the eluate. The previously transfused RBC unit was positive for presence of the K antigen. The patient's RBCs were negative for the presence of K antigen. Other laboratory data confirmed ongoing hemolysis, and a diagnosis of DHTR was made. She continued to display findings of active hemolysis for 9 more weeks requiring 19 units of RBCs. Thirty-four days after the original transfusion, her DAT remained positive and both the plasma sample and a RBC eluate demonstrated anti-K.
CONCLUSION: The delayed hemolytic transfusion reaction with hyperhemolysis can occur among patients without hemoglobinopathies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16371046     DOI: 10.1111/j.1537-2995.2005.00608.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  8 in total

1.  Hypothesis: hemolytic transfusion reactions represent an alternative type of anaphylaxis.

Authors:  Eldad A Hod; Set A Sokol; James C Zimring; Steven L Spitalnik
Journal:  Int J Clin Exp Pathol       Date:  2008-05-30

Review 2.  Postpartum hemorrhage: Blood product management and massive transfusion.

Authors:  Benjamin K Kogutt; Arthur J Vaught
Journal:  Semin Perinatol       Date:  2018-11-14       Impact factor: 3.300

3.  Increased detection of clinically significant antibodies and decreased incidence of delayed haemolytic transfusion reaction with the indirect antiglobulin test potentiated by polyethylene glycol compared to albumin: a Japanese study.

Authors:  Miho Okutsu; Hitoshi Ohto; Hiroyasu Yasuda; Kinuyo Kawabata; Satoshi Ono; Shunnichi Saito; Akiko Sugawara; Masami Kikuchi; Saori Miura; Youko Ishii; Kazuya Watanabe; Yuriko Tohyama; Kenneth E Nollet
Journal:  Blood Transfus       Date:  2010-11-26       Impact factor: 3.443

4.  Delayed Severe Hemolytic Transfusion Reaction During Pregnancy in a Woman with β-Thalassemia Intermediate: Successful Outcome After Eculizumab Administration.

Authors:  Giovanna Cannas; Léa Dubreuil; Axel Fichez; Mathieu Gerfaud-Valentin; Anne-Lise Debard; Arnaud Hot
Journal:  Am J Case Rep       Date:  2021-05-13

5.  Hyperhemolysis Syndrome without Underlying Hematologic Disease.

Authors:  Lauren Anne Eberly; Diaa Osman; Nathaniel Perryman Collins
Journal:  Case Rep Hematol       Date:  2015-02-17

6.  Delayed Hemolytic Transfusion Reaction in a Patient With Sickle Cell Disease and the Role of the Classical Complement Pathway: A Case Report.

Authors:  Pamela S Hair; Timothy P Heck; Daniel T Carr; Katherine D Watson; Jessica Price; Neel K Krishna; Kenji M Cunnion; William C Owen
Journal:  J Hematol       Date:  2021-02-06

7.  Acute Hyperhemolysis Syndrome in a Patient with Known Sickle Cell Anemia Refractory to Steroids and IVIG Treated with Tocilizumab and Erythropoietin: A Case Report and Review of Literature.

Authors:  Sasmith R Menakuru; Adelina Priscu; Vijaypal Dhillon; Ahmed Salih
Journal:  Hematol Rep       Date:  2022-07-21

Review 8.  Hyperhaemolytic Syndrome in Sickle Cell Disease: Clearing the Cobwebs.

Authors:  Anazoeze Jude Madu; Angela Ogechukwu Ugwu; Chilota Efobi
Journal:  Med Princ Pract       Date:  2020-11-11       Impact factor: 1.927

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.